INTRODUCTION {#S1}
============

Inflammatory responses activated by the innate immunity system constitute a highly efficient barrier in defending against diverse organismal insults. During an innate immune response, early local detection of the insult is mediated by the activation of pattern recognition receptors (PRRs) by pathogen- and damage-associated molecular patterns, which then triggers inflammation by stimulating the production and release of proinflammatory cytokines such as interleukin 1β (IL-1β), as well as pyroptosis, a proinflammatory form of cell death ([@R16]; [@R17]; [@R26]). Inflammation, however, must be tightly regulated, as excessive or chronic inflammation may lead to detrimental outcomes, including tissue damage or death as a result of septic shock.

Caspase-11, a member of the caspase family of cysteine proteases, is a critical mediator of inflammation and cell death ([@R11]; [@R33]). *Casp11^−/−^* mice are highly resistant to lipopolysaccharide (LPS)-induced septic shock, but are more sensitive to infection with *Burkholderia*, a cytosolic bacterium that escapes the vacuole, demonstrating the inflammatory response as a "double-edged sword" ([@R1]; [@R33]). Caspase-11 is highly inducible by activators of innate immunity such as LPS, interferon γ (IFN-γ), and IFN-β ([@R11], [@R12]; [@R20]; [@R27]; [@R32]). The expression of caspase-11 is required for caspase-1 activation and subsequent IL-1β secretion downstream of a subgroup of stimuli ([@R33]). Caspase-1 is directly involved in the processing of pro-IL-1β and the secretion of IL-1β. Caspase-11 potentiates caspase-1 activation downstream of noncanonical NLRP3 inflammasome activators, including diverse Gram-negative bacteria such as *Escherichia coli* ([@R14]; [@R33]), but is dispensable for the activation of caspase-1 downstream of canonical NLRP3 inflammasome activators such as extracellular ATP, the lysomotropic agent HLLOMe, and silica crystals, as well as other canonical inflammasome complexes such as the NLRC4 or AIM2 inflammasomes. In addition, caspase-11 triggers caspase-1-independent pyroptosis and subsequent release of proinflammatory factors such as IL-1α and HMGB1 downstream of noncanonical stimuli, including several vacuolar and cytosolic Gram-negative bacteria ([@R1]; [@R4]; [@R5]; [@R14]). Finally, caspase-11 modulates actin cytoskeleton dynamics and restricts *Legionella pneumophila* growth by promoting bacterial vacuole fusion with lysosomes, as well as by regulating cell migration ([@R2]; [@R21]). Caspase-11, which was first characterized in the late 1990s ([@R32], [@R33]), has recently received much attention ([@R4]; [@R27]). However, the downstream molecular effectors of caspase-11 remain to be identified. To the best of our knowledge, caspase-3 and caspase-11 itself are the only reported substrates for caspase-11 ([@R11]).

Transient receptor potential channel 1 (TRPC1) belongs to the canonical TRP subfamily of proteins with six transmembrane domains that assemble to form cation-permeable pores as homo- or heterotetramers ([@R6]). TRPC1 associates with other TRP channels, such as TRPC4 and TRPC5, as well as scaffolding proteins ([@R31]). The composition of these complexes determines the distribution of TRPC1 between the endoplasmic reticulum (ER) and the plasma membrane, as well as the various characteristics and gating mechanisms of the channels in which TRPC1 takes part. Although TRPC1 is widely expressed in a variety of tissues and is known to contribute to various physiological functions, it was not known to be involved in innate immunity.

Here, we identify TRPC1 as a substrate for caspase-11 that regulates inflammatory responses. Upon LPS treatment, caspase-11 induction leads to the degradation of TRPC1 in macrophages. TRPC1-deficient macrophages secrete increased amounts of mature IL-1β in response to NLRP3 activators without affecting caspase-1 cleavage or pyroptosis. In addition, *trpc1^−/−^* mice show higher IL-1β secretion in their sera following LPS injection. Our data provide a mechanism whereby caspase-11 promotes IL-1β release by degrading TRPC1 independently of caspase-1, and suggest that TRPC1 plays a role in regulating innate immunity by modulating channel complexes during inflammatory responses.

RESULTS {#S2}
=======

TRPC1 Is a Substrate for Caspase-11 {#S3}
-----------------------------------

A yeast two-hybrid screen identified TRPC1 as an interacting protein of inflammatory caspases (data not shown). When coexpressed in human embryonic kidney 293T (HEK293T) cells, the larger isoform of pro-caspase-11 (p43) coimmunoprecipitated with hemagglutinin-TRPC1 (HA-TRPC1; [Figure 1A](#F1){ref-type="fig"}). This interaction of TRPC1 with caspase-11 is selective because, among all TRPC channels, only TRPC1 and (with a lower affinity) TRPC2 could be immunoprecipitated with caspase-11 ([Figure S1](#SD2){ref-type="supplementary-material"}). Subunits p10 and p20 of caspase-11, but not caspase recruitment domain (CARD) alone, could be coimmunoprecipitated with TRPC1 ([Figure 1B](#F1){ref-type="fig"}). TRPC1 contains six transmembrane domains in its central part and two large N- and C-terminal cytosolic domains ([@R3]). FLAG-caspase-11 was able to coimmunoprecipitate independently with HA-TRPC1 N-terminal (HA-TRPC1-N) alone, the N-terminal domain with the transmembrane domain (HA-TRPC1-ΔC), and the transmembrane domain with the C-terminal domain (HA-TRPC1-ΔN), but not with the central transmembrane domain alone (HA-TRPC1-TM; [Figure 1C](#F1){ref-type="fig"}).

Since the catalytic domain (p20+p10) of caspase-11 interacts with the TRPC1 channel, we hypothesized that TRPC1 may be a substrate for caspase-11. Indeed, coexpression of caspase-11 and TRPC1 in HEK293T cells greatly decreased the levels of TRPC1 protein, which were restored upon addition of the caspase inhibitor z-VAD.fmk ([Figure 2A](#F2){ref-type="fig"}). Notably coexpression of the proteolytically inactive mutant caspase-11^C255G^ did not have any impact on the levels of TRPC1. Furthermore, incubation of purified recombinant caspase-11 p30 with S^35^-labeled TRPC1 in vitro led to the appearance of multiple TRPC1 fragments and a reduction of full-length TRPC1, which was inhibited by z-VAD.fmk ([Figure 2B](#F2){ref-type="fig"}). On the other hand, recombinant caspase-1 did not cleave TRPC1 in vitro, although it effectively cleaved pro-IL-1β ([Figures 2C](#F2){ref-type="fig"} and [S2A](#SD2){ref-type="supplementary-material"}). Coexpression of TRPC1 with caspase-1 did not lead to a reduction of TRPC1, contrary to that observed with caspase-11 ([Figure S2B](#SD2){ref-type="supplementary-material"}), although overexpressed caspase-1 could be coimmunoprecipitated with overexpressed TRPC1 ([Figure S2C](#SD2){ref-type="supplementary-material"}). Thus, TRPC1 is a substrate for caspase-11, but not caspase-1.

Given that the expression of caspase-11 is highly inducible by LPS ([@R32]), we next assessed the cleavage and levels of TRPC1 in LPS-treated cells. Ectopic HA-TRPC1 protein levels were substantially reduced 8 hr following LPS treatment, but not in the presence of the pan caspase inhibitor z-VAD.fmk or IDUN-6556, suggesting that TRPC1 is degraded by inflammatory caspases ([Figure S2D](#SD2){ref-type="supplementary-material"}). Consistently, the levels of endogenous TRPC1 protein decreased in primary macrophages upon LPS treatment, which induced the expression of caspase-11 ([Figure 2D](#F2){ref-type="fig"}). Strikingly, TRPC1 remained stable in *casp1^−/−^ casp11^−/−^*, and *casp11^−/−^* macrophages treated with LPS ([Figure 2E](#F2){ref-type="fig"}). On the other hand, the amounts of *trpc1* mRNA remained unchanged following LPS treatment of both wild-type (WT) and *casp11^−/−^* macrophages, excluding the possibility that TRPC1 is regulated at the transcriptional level ([Figure S2E](#SD2){ref-type="supplementary-material"}). Furthermore, we found that stimulation of primary macrophages with *E. coli* (J53 strain), which induced the expression of caspase-11, also led to a reduction in the levels of endogenous TRPC1 protein ([Figure 2F](#F2){ref-type="fig"}). Notably, TRPC1 levels remained stable in WT macrophages treated with low-dose LPS (1 ng/ml) for 3.5 hr followed by ATP, which was sufficient to lead to the secretion of caspase-1, but not sufficient to induce the expression of caspase-11 ([Figure S2F](#SD2){ref-type="supplementary-material"}). On the other hand, TRPC1 was degraded in WT, but not *casp11^−/−^*, macrophages treated with high-dose LPS (100 ng/ml) for 16 hr followed by ATP, which was sufficient to lead to expression of caspase-11 ([Figure S2F](#SD2){ref-type="supplementary-material"}). Thus, caspase-1 activation in the absence of caspase-11 expression does not lead to TRPC1 degradation. Taken together, these results suggest that TRPC1 is a physiologically relevant substrate of caspase-11 and is degraded in a caspase-11-dependent manner in macrophages upon induction of caspase-11 after the activation of TLR signaling.

Caspase-11 Controls the TRPC1-Dependent Decrease in Cytosolic Ca^2+^ following LPS Treatment {#S4}
--------------------------------------------------------------------------------------------

Since TRPC1 is a membrane protein that can form channels permeable to Ca^2+^, we next assessed the effect of TRPC1 and caspase-11 on macrophages' cytosolic Ca^2+^ concentration in response to LPS stimulation. We found that during continuous LPS treatment, cytosolic Ca^2+^ concentration demonstrated a transient increase at 2 hr followed with a sustained decrease for up to 10 hr ([Figure 3A](#F3){ref-type="fig"}). Interestingly, this sustained decrease of Ca^2+^ concentration is dependent on caspase-11 and TRPC1, as no reduction of cytosolic Ca^2+^ concentration was observed in either *trpc1^−/−^* or *casp11^−/−^* macrophages at 10 hr after LPS treatment ([Figure 3B](#F3){ref-type="fig"}). Thus, we conclude that TRPC1 cleavage by caspase-11 has a functional impact on Ca^2+^ flux after LPS stimulation.

TRPC1 Deficiency Promotes IL-1β Release but Has No Effect on Caspase-1 Activation or Pyroptosis {#S5}
-----------------------------------------------------------------------------------------------

Next, we investigated the implication of TRPC1 in the inflammatory response regulated by caspase-11. Caspase-11 is a critical mediator of LPS-induced septic shock ([@R32], [@R33]); therefore, we first assessed the response of *trpc1^−/−^* mice to intraperitoneally injected LPS. Indeed, *trpc1^−/−^* mice showed significantly higher levels of IL-1β in serum following LPS injection as compared with WT mice, indicating that TRPC1 modulates inflammation in vivo by inhibiting IL-1β secretion ([Figure 4A](#F4){ref-type="fig"}). On the other hand, *trpc1^−/−^* mice did not exhibit higher constitutive levels of circulating IL-1β in basal conditions, suggesting that the absence of TRPC1 alone is not sufficient to elicit an inflammatory response ([Figure S3A](#SD2){ref-type="supplementary-material"}). At the cellular level, caspase-11 is required for caspase-1 activation, IL-1β and IL-18 secretion, and pyroptosis in macrophages infected with *E. coli* ([@R14]). Consistently, *trpc1^−/−^* macrophages showed higher secretion of mature IL-1β and IL-18 in response to *E. coli* ([Figures 4B--4D](#F4){ref-type="fig"}). Since TRPC1 deficiency did not have any effect on caspase-1 cleavage, as indicated by the normal appearance of the caspase-1 subunit p20, we conclude that the cleavage of TRPC1 likely impacts events downstream of caspase-1 activation, including the unconventional secretion pathway that is responsible for mature IL-1β release. Interestingly, *trpc1^−/−^* macrophages also showed increased mature IL-1β release triggered by canonical NLRP3 inflammasome activators such as ATP, HLLOMe, and silica, which is independent of caspase-11 ([@R14]), but showed no difference in caspase-1 cleavage ([Figures 4E and 4F](#F4){ref-type="fig"}). We thus conclude that LPS priming modulates the TRPC1 complexes by both caspase-11-dependent and -independent, redundant mechanisms. Notably, TRPC1 deficiency did not lead to any increase in the levels of pro-IL-1β, or secretion of TNF-α following LPS priming, ruling out a role of TRPC1 in TLR4 signaling ([Figures 4C, 4F](#F4){ref-type="fig"}, and [S3B](#SD2){ref-type="supplementary-material"}). In addition, TRPC1-deficiency did not sensitize cells to caspase-11-dependent pyroptosis following infection by *E. coli*, or to caspase-1-dependent pyroptosis induced by canonical stimuli, including ATP and HLLOMe ([Figures S3C--S3F](#SD2){ref-type="supplementary-material"}), supporting the notion that pyroptosis occurs independently of TRPC1 degradation.

DISCUSSION {#S6}
==========

In this study, we describe the involvement of the cationic channel subunit TRPC1 in promoting mature IL-1β release upon inactivation by caspase-11-mediated cleavage in response to Gram-negative bacteria *E. coli* and LPS. Our identification of TRPC1 as a substrate for caspase-11, and evidence for its degradation upon LPS-induced caspase-11 expression, suggest that the TRPC1 complex is remodeled at the onset of inflammation and plays a role in regulating innate immunity. Consistently, *trpc1^−/−^* macrophages show increased secretion of mature IL-1β upon infection by *E. coli* or stimulation with LPS together with extracellular ATP or lysosome disruption, but show no defect in caspase-1 cleavage or pyroptosis, suggesting that remodeling of the TRPC1 complex regulates the unconventional secretion pathway independently of caspase-1 activation. Thus, our results demonstrate a role for caspase-11 in regulating IL-1β secretion through the degradation of TRPC1 and the remodeling of associated channel complexes independently of caspase-1.

As we reported previously ([@R11]), *casp1^−/−^* mice, which were independently generated by two separate groups, do not express caspase-11 and accordingly should be referred to as *casp1^−/−^ casp11^−/−^* mice. *Casp1^−/−^* Casp11^Tg^ mice that are deficient for caspase-1 and express caspase-11 were generated recently and helped to clarify the distinct functional roles of caspase-1 and caspase-11 in innate immunity ([@R14]). Importantly, caspase-11, but not caspase-1, is critical for sensitivity to LPS-induced septic shock and confers resistance against two pathogenic species of Gram-negative *Burkholderia*; therefore, caspase-11 is an important regulator of inflammation ([@R14]; [@R27]; [@R32], [@R33]). Caspase-11 is unique among caspases in that it is highly regulated at levels of transcription upon the activation of inflammatory responses ([@R32], [@R33]). Pro-caspase-11 is inducible upon stimulation of multiple ligands involved in innate immunity, including LPS, IFNγ, and type I IFN ([@R4]; [@R7]; [@R10]; [@R20]; [@R23]; [@R27]; [@R28]; [@R33]; [@R34]). Whether expression of caspase-11 is sufficient for its autoactivation is the subject of debate ([@R4]; [@R11], [@R13]; [@R27]; [@R33]). Indeed, although pro-caspase-11 induction by extracellular LPS or IFNγ is sufficient for its autoprocessing in the p30 form, an additional signal that was recently identified to be cytosolic LPS is required to trigger caspase-11-dependent pyroptosis and caspase-1 activity ([@R4]; [@R8]; [@R15]; [@R27]). However, due to the lack of a specific caspase-11 activity assay and identification of a caspase-11-specific substrate, caspase-11 activity per se was not assessed in previous studies. Therefore, cytosolic LPS may also control pyroptosis and caspase-1 activation by acting downstream of caspase-11 activation. Detection of autoprocessed p30 demonstrates that caspase-11 is active in macrophages treated with extracellular LPS ([@R27]). In the present study, we show that TRPC1 is degraded by caspase-11 in macrophages treated with extracellular LPS, demonstrating that caspase-11 can be activated without triggering pyroptosis.

Despite the high interest in caspase-11, very few of its substrates have been identified. Caspase-11 can control cell mobility and intracellular vesicular trafficking by modulating actin cytoskeleton independently of its protease activity ([@R2]; [@R21]). On the other hand, caspase-11 is capable of autoprocessing ([@R11]). In addition, direct cleavage of caspase-3 by caspase-11 was shown to contribute to deleterious cell death in several animal models of neurodegenerative disease ([@R9]; [@R11]; [@R30]). However, the requirement for caspase-3 in caspase-11-dependent pyroptosis has not yet been investigated ([@R12]; [@R14]). Lastly, the molecular mechanism of caspase-11-dependent caspase-1 activation downstream of noncanonical NLRP3 activators is unknown. Although caspase-11 associates with caspase-1, caspase-1 is not a direct substrate for caspase-11 ([@R33]). Thus, TRPC1 constitutes the only noncaspase substrate for caspase-11 identified so far.

TRPC1 assembles with other TRPCs to form heterotetrameric cation-permeable channels with current characteristics different from those of homotetramers ([@R31]). In particular, TRPC1 reduces the Ca^2+^ permeability of the respective channels in homodimers while participating in the channel pore of at least TRPC3, TRPC4, and TRPC5. TRPC1 also inhibits TRPV6 expression at the plasma membrane ([@R29]; [@R31]). In neurons, TRPC1 forms a complex with TRPC5 that localizes at the plasma membrane ([@R31]). However, TRPC1 cannot be detected at the plasma membrane in macrophages where TRPC5 is not expressed ([@R19]). Given the complexity of these functional interactions, TRPC1 degradation during an inflammatory response may alter the gating properties of TRPC1-containing channels in the plasma or intracellular membranes to promote unconventional protein secretion.

TRPC1 deficiency increases the secretion of mature IL-1β and IL-18 by macrophages without affecting pyroptosis or the cleavage of caspase-1. Thus, caspase-11 regulates IL-1β and IL-18 secretion both at the cytokine maturation level through caspase-1 and at the extracellular release level through TRPC1. Notably, TRPC1 deficiency potentiates not only caspase-11-dependent IL-1β secretion but also caspase-11-independent IL-1 secretion, suggesting a potentially wider role of TRPC1 in regulating secretion. Since TRPC1 degradation induced by LPS strictly depends on caspase-11, LPS priming may modulate the channelosome through redundant TRPC1- and caspase-11-independent mechanisms, and bypass the caspase-11 requirement in unconventional protein secretion in response to canonical NLRP3 stimulation. It would be interesting to investigate the roles of caspase-11 and caspase-1 in modulating other TRP channel activities in other inflammatory responses.

Taken together, our data point to a role of cationic channels in the downstream process of unconventional secretion of IL-1β and IL-18, and suggest that in addition to its already described regulatory functions in the cytoskeleton, cell death, and caspase-1 activation, caspase-11 controls IL-1β and IL-18 release by modulating the cationic channel composition of the cell. Our results also suggest a possible role for the TRPC1-associated channelosome in regulating unconventional secretion in general, which needs to be investigated in future studies.

EXPERIMENTAL PROCEDURES {#S7}
=======================

Mice {#S8}
----

C57B6, *casp11^−/−^* ([@R33]), *casp1^−/−^* mice deficient for both caspase-1 and caspase-11 (*casp1^−/−^ casp11^−/−^* mice) ([@R11]; [@R18]), and *trpc1^−/−^* ([@R25]) mice were housed at the Warren Alpert Animal Facility (Harvard Medical School) and Children's Hospital Animal Facility under specific pathogen-free conditions. Experiments were performed in accordance with federal and institutional guidelines. The mice received food and water ad libitum. Inflammatory peritoneal macrophages were elicited by intraperitoneal injection of 0.75 ml thioglycolate broth and harvested by peritoneal wash 4 days later.

Cell-Growth Conditions {#S9}
----------------------

HEK293T and LN-18 cells were maintained in Dulbecco's modified Eagle's medium (DMEM) and DMEM/F12 (GIBCO), respectively, supplemented with 1× penicillin/streptomycin (PS; GIBCO) and 10% fetal bovine serum (FBS; GIBCO). Inflammatory peritoneal macrophages were cultured at 0.5--1 × 10^6^ cells/ml in DMEM (GIBCO) supplemented with 1× PS and 10% FBS. For all *E. coli* infection experiments, cells were grown in the absence of PS. For trichloroacetic acid (TCA) precipitation of the media, cells were rinsed and treated in DMEM+PS without serum.

Activation of the Inflammasome {#S10}
------------------------------

*E. coli* (strain J53) were grown in lysogeny broth (LB) to log expansion phase, resuspended in PBS, and added to macrophages. For IL-1β secretion assay, gentamycin (50 μg/ml) was added 1.5 hr after infection and supernatant was collected after a total of 16 hr following infection.

Constructs {#S11}
----------

Constructs coding for FLAG-caspase-11, FLAG-caspase-11CARD98 (aa 1--98), FLAG-caspase-11CARD103 (aa 1--103), FLAG-caspase-11p30, FLAG-caspase-11p10, pcDNA-IL-1β, and pcDNA-Casp11^C255G^ were previously described ([@R22]). FLAG-caspase-11p20 (aa 79--285) was cloned in pFLAG3X. HA-TRPC1, HA-TRPC1DC (deleted of the C-terminal domain, aa 1--649), HA-TRPC2, HA-TRPC3, HA-TRPC4, HA-TRPC5, and HA-TRPC6 were kind gifts from P.F. Worley and J. Yuan ([@R35]). HA-TRPC1-N (N-terminal domain, aa 1--315), HA-TRPC1ΔN (deleted of the N-terminal domain, aa 306--760), HA-TRPC1-TM (transmembrane domain, aa 306--613) were cloned following PCR amplification.

Reagents {#S12}
--------

The following reagents were used: LPS from *E. coli* 0111:B4, ATP, and nigericin (Sigma-Aldrich); silica (MIN-U-SIL 5; U.S. Silica); HLLOMe (Chem-Impex International); z-VAD-fmk (Alexis); and IDUN-6556 ([@R24]).

Immunoprecipitation {#S13}
-------------------

For coimmunoprecipitation experiments, HEK293T cells were lysed in lysis buffer (Tris HCl, pH 7.6 50 mM, NaCl 400 mM, NP-40 1%, PMSF 1 mM, and protease inhibitors). HA-TRPC1 and FLAG-caspase-11 were immunoprecipitated with anti-HA and anti-FLAG M2 agarose beads (Sigma-Aldrich), respectively, for 4 hr at 4°C. Immunoprecipitations were washed in lysis buffer and proteins were eluted in Laemmli sample buffer 2×. For anti-TRPC1 immunoprecipitation, 5 × 10^6^ macrophages were lysed in RIPA buffer. TRPC1 was immunoprecipitated using protein A/G UltraLink resin (Thermo Scientific) and anti-TRPC1 antibody (Millipore), and eluted in Laemmli sample buffer.

Transfection {#S14}
------------

HEK293T cells were transfected using the CaCl~2~ procedure. LN-18 cells were transfected using transIT-LT1 transfection reagent (Mirus Bio).

Western Blot Analysis {#S15}
---------------------

Samples were analyzed by SDS-PAGE, transferred to PVDF membranes, blocked, and probed according to standard procedures. The following antibodies were used: anti-caspase-11 ([@R33]), anti-caspase-1 ([@R33]), anti-HA (Santa Cruz biotechnology), anti-FLAG M2 (Sigma-Aldrich), anti-TRPC1 (Millipore), anti-actin (Millipore), anti-IL-1β (R&D Systems), anti-IL-18 (MBL), and anti-laminB (Santa Cruz).

In Vitro Caspase Cleavage Assay {#S16}
-------------------------------

In vitro production of ^35^S-labeled TRPC1 and IL-1β was performed using TNT-coupled transcription/translation kits (Promega). Purification of recombinant Caspase-11 p30 and in vitro cleavage assay by recombinant Caspase-11 p30 or active human Caspase-1 (p30; Chemicon International) were performed as described previously ([@R11]).

ELISA {#S17}
-----

In vitro secretion of IL-1β and TNF-α in macrophage culture supernatants was measured using mouse IL-1β/IL-1F2 and TNF-α DuoSet kits (R&D Systems). In vivo secretion of IL-1β in the serum was assessed using the mouse IL-1β/IL-1F2 Quantikine kit (R&D).

Intracellular Ca^2+^ Measurement {#S18}
--------------------------------

Cells were loaded with the ratiometric Ca^2+^ indicator Fura-2/AM in Opti-MEM (at 37°C, 5% CO~2~) for 30 min, washed, and incubated for an additional 15 min prior to imaging. Ca^2+^ imaging was performed in Ringer's solution containing 2 mM Ca^2+^. Excitation was carried out at 340 nm and 380 nm using a Lambda DG4 Ultra High Speed Wavelength Switcher (Sutter Instrument), and emission was collected at 510 ± 10 nm using a Hamamatsu Orca R2 CCD camera and Slidebook data acquisition software.

Cytotoxicity Assay {#S19}
------------------

Cell death was measured as the percentage of lactate dehydrogenase (LDH) release according to standard protocols. DMEM+10% FBS was used as the blank control, and supernatants of control cells treated with Triton X-100 0.01% were used to measure total LDH release. Cell death was measured by propidium iodide (PI) incorporation. PI (1 μg/ml) was added to the cell culture media, and cells were observed by live imaging using a Nikon Ti inverted microscope equipped with a 10× Plan Apo NA 0.3 objective lens. Images were acquired with a Hamamatsu ORCA-R2 cooled CCD camera controlled with MetaMorph 7 software (Molecular Devices).

Supplementary Material {#S20}
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![Caspase-11 Interacts with TRPC1\
(A) Lysates of HEK293T cells expressing HA-TRPC1 and FLAG-Casp11 were subjected to anti-HA immunoprecipitation. The western blots were analyzed using anti-caspase-11 and anti-HA.\
(B) Lysates of HEK293T cells expressing HA-TRPC1 and FLAG-Casp11, FLAG-Casp11-CARD98, FLAG-Casp11-CARD103, FLAG-Casp11-p30, FLAG-Casp11-p20, or FLAG-Casp11-p10 were subjected to anti-HA immunoprecipitation. The western blots were analyzed using anti-FLAG and anti-HA.\
(C) Lysates of HEK293T cells expressing FLAG-Casp11 and HA-TRPC1, HA-TRPC1-N, HA-TRPC1-ΔC, HA-TRPC1-ΔN, or HA-TRPC1-TM were subjected to anti-HA immunoprecipitation. Diagrams of TRPC1 association with membrane and truncation expression constructs of TRPC1 are shown; gray sections represent transmembrane spans. The western blots were analyzed using anti-caspase-11 and anti-HA.\
See also [Figure S1](#SD2){ref-type="supplementary-material"}.](nihms567304f1){#F1}

![TRPC1 Is a Substrate of Caspase-11 and Degraded following LPS Treatment\
(A) HEK293T cells were cotransfected with expression vectors of HA-TRPC1 and FLAG-Casp11 or Casp11^C255G^ catalytic mutant, and cultured for 48 hr. z-VAD.fmk (20 μM) was added as indicated for the last 24 hr of culture. The levels of HA-TRPC1 protein were assessed by western blotting using anti-HA, anti-caspase-11, and anti-actin (as a control).\
(B) In vitro cleavage assay of ^35^S-labeled TRPC1 by purified recombinant caspase-11 p30.\
(C) TRPC1 is not a substrate of caspase-1. In vitro cleavage assay of ^35^S-labeled TRPC1 by recombinant caspase-1 p30.\
(D--F) Macrophages from WT (D) or *casp11^−/−^* or *casp1^−/−^ casp11^−/−^* mice (E) were treated with LPS (100 ng/ml) for 16 hr. Macrophages from WT mice were infectedwith *E. coli* (J53strain, moi20) for 16hr (F). The expression levels of endogenous TRPC1 were assessed by anti-TRPC1 immunoprecipitation followed by anti-TRPC1 western blotting.\
See also [Figure S2](#SD2){ref-type="supplementary-material"}.](nihms567304f2){#F2}

![LPS Triggers a Caspase-11- and TRPC1-Dependent Cytosolic Ca^2+^ Decrease\
(A) Macrophages from WT mice were treated with LPS (100 ng/ml) for the indicated times. Intracellular Ca^2+^ was measured through ratiometric imaging of Fura-2AM (F340/F380). Error bars indicate SE from the mean.\
(B) WT, *trpc1^−/−^*, and *casp11^−/−^* macrophages were treated with LPS (100 ng/ml, red bars) for 10 hr or left untreated (blue bars). Intracellular Ca^2+^ was measured through ratiometric imaging of Fura-2AM (F340/F380). Error bars indicate SE.](nihms567304f3){#F3}

![TRPC1 Inhibits Mature IL-1β Release\
(A) *Trpc1^−/−^* mice secrete more IL-1β than WT mice in the serum following LPS challenge. WT and *trpc1^−/−^* mice were injected intraperitoneally with LPS (4 mg/kg). The sera were harvested after 4 hr (n = 6) or 8 hr (n = 8--9). IL-1β secretion in sera was assessed by ELISA. Error bars represent SE. Untreated mice were used as negative control (−). t test, \*p \< 0.05.\
(B) Macrophages from WT, *trpc1^−/−^*, and *casp11^−/−^* mice were infected with *E. coli* for 16 hr, and secretion of mature IL-1β in the culture supernatant was assessed by ELISA. Error bars indicate SD from the mean.\
(C and D) Caspase-11, caspase-1, IL-1β, IL-18 expression level, cleavage, and secretion were assessed by western blotting of cell lysates and TCA-precipitated culture media.\
(E) Macrophages from WT, *trpc1^−/−^*, and *casp11^−/−^* mice were treated with LPS (100 ng/ml, 8 hr) followed by ATP (30 min), HLLOMe (30 min), or silica (2 hr) at the indicated concentrations. Mature IL-1β in the culture supernatant was assessed by ELISA. Error bars indicate SD.\
(F) Caspase-11, caspase-1, IL-1β expression level, cleavage, and secretion were assessed by western blot on cell lysates and TCA-precipitated culture media.\
See also [Figure S3](#SD2){ref-type="supplementary-material"}.](nihms567304f4){#F4}

[^1]: Present address: Department of Pharmacology, University of Virginia School of Medicine, Charlottesville, VA 22908, USA
